Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 16,674,766
- Estimated value
- $13,211,417
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Shares held by ElevateBio LLC
David Hallal - Director at Kalaris Therapeutics, Inc.
Issuer-level insider activity
- Role
- Director
- Issuer ticker
- KLRS on Nasdaq
- Entity type
- Individual
- Source filing history
- Open source filing history
Identity
Names, identifiers, and filing context for this profile.
1 identity field
Source evidence
Original filing metadata and source links for verification.
1 source field
No buys or sells have been reported by David Hallal since 19 Aug 2025
Reported holdings for David Hallal in Kalaris Therapeutics, Inc.
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 2,143,662
- Estimated value
- $1,698,423
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Direct
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 720,965
- Estimated value
- $571,221
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Shares held by The Hallal Family Irrevocable Trust 2012
Form 4 holding
Director
Allovir, Inc.
- Security class
- Common Stock
- Shares / value
- 138,153
- Estimated value
- $109,459
- Report date
- 06 Jun 2024
- Price
- $0.7923
- Ownership
- Shares held by Terrie A. Hallal Family Irrevocable Trust 2012
Form 4 holding
Director
Kalaris Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 9,000
- Estimated value
- Report date
- 03 Jun 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Transaction history for David Hallal in Kalaris Therapeutics, Inc.
| Sym | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares after | Date | Ownership |
|---|
* marks a reported price that did not pass the local price check.